The ANG-(1-7)/ACE2/mas Axis in the Regulation of Nephron Function

Overview

Journal Am J Physiol Renal Physiol

Publisher American Physiological Society

Specialties Nephrology
Physiology

Date 2010 Apr 9

PMID 20375118

Citations 77

Authors

Carlos M Ferrario

Jasmina Varagic

Affiliations

Soon will be listed here.

Abstract

The study of experimental hypertension and the development of drugs with selective inhibitory effects on the enzymes and receptors constituting the components of the circulating and tissue renin-angiotensin systems have led to newer concepts of how this system participates in both physiology and pathology. Over the last decade, a renewed emphasis on understanding the role of angiotensin-(1-7) and angiotensin-converting enzyme 2 in the regulation of blood pressure and renal function has shed new light on the complexity of the mechanisms by which these components of the renin angiotensin system act in the heart and in the kidneys to exert a negative regulatory influence on angiotensin converting enzyme and angiotensin II. The vasodepressor axis composed of angiotensin-(1-7)/angiotensin-converting enzyme 2/mas receptor emerges as a site for therapeutic interventions within the renin-angiotensin system. This review summarizes the evolving knowledge of the counterregulatory arm of the renin-angiotensin system in the control of nephron function and renal disease.

Citing Articles

Effect of carbon black and silicon dioxide nanoparticle exposure on corona receptor ACE2 and TMPRSS2 expression in the ocular surface.

Li X, Li X, Kang B, Eom Y, Kim D, Song J Sci Rep. 2024; 14(1):27023.

PMID: 39506016 PMC: 11542009. DOI: 10.1038/s41598-024-78518-9.

Role of vitamin D in COVID-19 and other viral infections.

Engin M, Ozdemir O World J Virol. 2024; 13(3):95349.

PMID: 39323448 PMC: 11401007. DOI: 10.5501/wjv.v13.i3.95349.

Targeting the epidermal growth factor receptor (EGFR/ErbB) for the potential treatment of renal pathologies.

Tawengi M, Al-Dali Y, Tawengi A, Benter I, Akhtar S Front Pharmacol. 2024; 15:1394997.

PMID: 39234105 PMC: 11373609. DOI: 10.3389/fphar.2024.1394997.

Alternative Renin-Angiotensin System.

Bader M, Steckelings U, Alenina N, Santos R, Ferrario C Hypertension. 2024; 81(5):964-976.

PMID: 38362781 PMC: 11023806. DOI: 10.1161/HYPERTENSIONAHA.123.21364.

The renin-angiotensin-aldosterone system (RAAS) signaling pathways and cancer: foes versus allies.

Hassani B, Attar Z, Firouzabadi N Cancer Cell Int. 2023; 23(1):254.

PMID: 37891636 PMC: 10604988. DOI: 10.1186/s12935-023-03080-9.

References

Magaldi A, Cesar K, de Araujo M, Simoes E Silva A, Santos R . Angiotensin-(1-7) stimulates water transport in rat inner medullary collecting duct: evidence for involvement of vasopressin V2 receptors. Pflugers Arch. 2003; 447(2):223-30. DOI: 10.1007/s00424-003-1173-1. View

Menon J, Soto-Pantoja D, Callahan M, Cline J, Ferrario C, Tallant E . Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Res. 2007; 67(6):2809-15. DOI: 10.1158/0008-5472.CAN-06-3614. View

MUIRHEAD E . Renal vasodepressor mechanisms: the medullipin system. J Hypertens Suppl. 1993; 11(5):S53-8. View

Herath C, Warner F, Lubel J, Dean R, Jia Z, Lew R . Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis. J Hepatol. 2007; 47(3):387-95. PMC: 7114685. DOI: 10.1016/j.jhep.2007.03.008. View

Benter I, Yousif M, Dhaunsi G, Kaur J, Chappell M, Diz D . Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. Am J Nephrol. 2007; 28(1):25-33. DOI: 10.1159/000108758. View

Alfany-Fernandez I, Casillas-Ramirez A, Bintanel-Morcillo M, Brosnihan K, Ferrario C, Serafin A . Therapeutic targets in liver transplantation: angiotensin II in nonsteatotic grafts and angiotensin-(1-7) in steatotic grafts. Am J Transplant. 2009; 9(3):439-51. DOI: 10.1111/j.1600-6143.2008.02521.x. View

Petty W, Miller A, McCoy T, Gallagher P, Tallant E, Torti F . Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clin Cancer Res. 2009; 15(23):7398-404. PMC: 3703919. DOI: 10.1158/1078-0432.CCR-09-1957. View

Wysocki J, Ye M, Rodriguez E, Gonzalez-Pacheco F, Barrios C, Evora K . Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension. 2009; 55(1):90-8. PMC: 2827767. DOI: 10.1161/HYPERTENSIONAHA.109.138420. View

Su Z, Zimpelmann J, Burns K . Angiotensin-(1-7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells. Kidney Int. 2006; 69(12):2212-8. DOI: 10.1038/sj.ki.5001509. View

10.

Burgelova M, Kramer H, Teplan V, Velickova G, Vitko S, Heller J . Intrarenal infusion of angiotensin-(1-7) modulates renal functional responses to exogenous angiotensin II in the rat. Kidney Blood Press Res. 2002; 25(4):202-10. DOI: 10.1159/000066340. View

11.

Oliveira M, Carvalho M, Nigro D, Passaglia R, Fortes Z . Angiotensin-(1-7) and bradykinin interaction in diabetes mellitus: in vivo study. Peptides. 2002; 23(8):1449-55. DOI: 10.1016/s0196-9781(02)00080-3. View

12.

Trask A, Averill D, Ganten D, Chappell M, Ferrario C . Primary role of angiotensin-converting enzyme-2 in cardiac production of angiotensin-(1-7) in transgenic Ren-2 hypertensive rats. Am J Physiol Heart Circ Physiol. 2007; 292(6):H3019-24. DOI: 10.1152/ajpheart.01198.2006. View

13.

Santos R, Silva A, Magaldi A, Khosla M, Cesar K, Passaglio K . Evidence for a physiological role of angiotensin-(1-7) in the control of hydroelectrolyte balance. Hypertension. 1996; 27(4):875-84. DOI: 10.1161/01.hyp.27.4.875. View

14.

van der Wouden E, Ochodnicky P, van Dokkum R, Roks A, Deelman L, de Zeeuw D . The role of angiotensin(1-7) in renal vasculature of the rat. J Hypertens. 2006; 24(10):1971-8. DOI: 10.1097/01.hjh.0000244945.42169.c0. View

15.

Heller J, Kramer H, Maly J, cervenka L, HORACEK V . Effect of intrarenal infusion of angiotensin-(1-7) in the dog. Kidney Blood Press Res. 2000; 23(2):89-94. DOI: 10.1159/000025959. View

16.

Clark M, Tallant E, Tommasi E, Bosch S, Diz D . Angiotensin-(1-7) reduces renal angiotensin II receptors through a cyclooxygenase-dependent mechanism. J Cardiovasc Pharmacol. 2003; 41(2):276-83. DOI: 10.1097/00005344-200302000-00017. View

17.

Cervenka L, Horacek V, Vaneckova I, Hubacek J, Oliverio M, Coffman T . Essential role of AT1A receptor in the development of 2K1C hypertension. Hypertension. 2002; 40(5):735-41. DOI: 10.1161/01.hyp.0000036452.28493.74. View

18.

Wang G, Lai F, Lai K, Chow K, Kwan C, Li K . Urinary mRNA expression of ACE and ACE2 in human type 2 diabetic nephropathy. Diabetologia. 2008; 51(6):1062-7. DOI: 10.1007/s00125-008-0988-x. View

19.

Ye M, Wysocki J, William J, Soler M, Cokic I, Batlle D . Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol. 2006; 17(11):3067-75. DOI: 10.1681/ASN.2006050423. View

20.

Pignone A, Rosso A, Brosnihan K, Perfetto F, Livi R, Fiori G . Reduced circulating levels of angiotensin-(1--7) in systemic sclerosis: a new pathway in the dysregulation of endothelial-dependent vascular tone control. Ann Rheum Dis. 2007; 66(10):1305-10. PMC: 1994289. DOI: 10.1136/ard.2006.064493. View